Meihua International Medical Technologies Co., Ltd. Received Nasdaq Delisting Notice

Core Viewpoint - Meihua International Medical Technologies Co., Ltd. is facing delisting from Nasdaq due to non-compliance with listing rules, specifically failing to maintain a minimum bid price and the required number of publicly held shares [1][5]. Group 1: Delisting Details - On December 2, 2025, Nasdaq notified Meihua of the delisting determination due to failure to regain compliance with Listing Rule 5550(a)(2) [1]. - The company was previously informed on December 3, 2024, that its share price had been below $1 for 30 consecutive business days, violating Listing Rule 5450(a)(1) [2]. - Meihua executed a reverse share split of 1:16 on November 24, 2025, but did not meet the $1.00 minimum bid price requirement for 10 consecutive business days before December 1, 2025 [3]. Group 2: Compliance and Appeal - The company was given until December 9, 2025, to appeal the delisting decision, and it submitted a hearing request on December 4, 2025 [4]. - As of December 1, 2025, Meihua was also found to have less than 500,000 publicly held shares, which is another basis for delisting under Listing Rule 5550(a)(4) [5]. Group 3: Company Overview - Meihua International Medical Technologies Co., Ltd. manufactures and provides Class I, II, and III disposable medical devices, with over 1,000 types of products for domestic sales and more than 120 products exported to over 30 countries [6]. - The company has received international "CE" certification and ISO 13485 system certification, and is registered with the FDA for over 20 Class I products [6].